NMPA
Mabwell Receives FDA IND Clearance for Novel IBD Antibody 9MW5211
The Shanghai-based biopharmaceutical company announced this week that 9MW5211 received FDA IND clearance to begin clinical studies in inflammatory bowel disease. Simultaneously, China’s National Medical Products Administration accepted clinical trial applications for multiple indications including IBD and multiple sclerosis for review. The compound is described as the world’s first clinical-stage drug candidate for its specific…
